<DOC>
	<DOCNO>NCT00211848</DOCNO>
	<brief_summary>The primary aim investigation evaluate effect combine antiviral , antifibrotic antioxidant treatment progression liver disease patient hepatitis C either abstain alcohol continue drink . All subject give state-of-the-art antiviral treatment ( pegylated interferon + ribavirin ) , supplement either placebo polyenylphosphatidylcholine ( PPC ) , purified soybean extract consist 95-96 % polyunsaturated phosphatidylcholines ( PC ) antifibrotic antioxidant property . Secondary aim verify whether moderate alcohol consumption interfere antiviral effect pegylated interferon + ribavirin HCV validate reliability various circulate marker substitute liver biopsy indicate stage liver pathology propensity progression .</brief_summary>
	<brief_title>Antiviral &amp; Antifibrotic Liver Therapy HCV + Drinkers Non-Drinkers</brief_title>
	<detailed_description>Current therapy HCV disease focus anti-viral treatment . The combination pegylated interferon ribavirin approve FDA treat HCV disease . Subjects study give ribavirin pegylated interferon . One innovative aspect proposal state-of-the-art antiviral treatment supplement anti-fibrotic agent , namely polyenylphosphatidylcholine ( PPC ) , placebo , administer double blind randomized fashion . Current therapy focus anti-viral treatment , neglect fact cause medical symptom eventually demise HCV patient liver fibrosis , result cirrhosis associate complication , include hepatocellular carcinoma . If fibrotic process could stop even prevent , hepatitis C virus would lose much impact health . Available anti-fibrotic agent toxic use patient , except one , namely PPC , show various experimental model strike anti-fibrotic action , find recently , European study , beneficial patient hepatitis C term circulate level transaminase . Various study indicate HCV associate oxidative stress thus noteworthy PPC discover also significant anti-oxidant effect . The study approve Institutional Review Board Center , patient provide write informed consent . After screen , patient randomly assign one 2 treatment group ( PPC placebo ) . The two treatment group give combination pegylated interferon ( 180 μg injected weekly ) ( Shiffman et al , 1999 ; Sulkowski et al , 1999 ) , ribavirin 48 week ( genotype I ) 24 week ( genotype ) . If latter respond term HCV RNA , also treat 48 week . Ribavirin administer orally twice day total daily dose 1000 mg patient weigh 75 kg less 1200 mg weigh 75 kg . These drug start stop time , PPC ( 5 chewable tablet 0.9 gm per day ) correspond placebo ( obtain PHOSPHOLIPID GmbH , successor Rhone-Poulenc Rorer , Cologne , Germany ) give patient 3 year . The patient hemoglobin fall 2 g per deciliter follow every 2 week stabilization . The dose ribavirin reduce 600 mg per day patient whose hemoglobin concentration fall 10 g per deciliter , discontinue concentration fall 8.5 g per deciliter . For severe adverse event anemia , dose interferon reduce half dose ribavirin 600 mg per day . The full dose resume event , discontinue effect persist . The patient evaluate outpatient week 1 , 2 , 4 every 4 week 24-48 week interferon-ribavirin-PPC ( placebo ) treatment well subsequent PPC ( placebo ) therapy . Upon cessation antiviral treatment , study patient may see quarterly basis , Investigator 's judgment , flexible schedule impact negatively patient care impact positively patient retention . Biochemical testing perform central laboratory . Plasma HCV RNA level determine treatment , interferon-ribavirin treatment 24 48 week , interferon-ribavirin therapy month 18 , 24 30 end 3 year . Plasma HCV RNA measure quantitative reverse-transcription-polymerase-chain-reaction assay ( Cobas Amplicor HCV Monitor v.2 , Roche Diagnostic Systems , Inc. ) sensitivity 3000 IU/ml linearity 2.5 X 106 IU/ml . Samples negative quantitative HCV-RNA retested qualitative HCV-PCR assay ( Cobas Amplicor HCV 2.0 , Roche Diagnostic Systems , Inc. ) sensitivity 60 IU/ml . HCV genotyping carry accord Stuyver et al , ( 1993 ; Inno-LIPA HCVII , Immunogenetics ) . Compliance term PPC ( placebo ) monitor 4 method : patient diary , pill count medication monthly urine analysis presence riboflavin marker . Patients consume 60 mg riboflavin per day . Riboflavin rapidly excrete urine fluorescent pass ultraviolet lamp . In addition , spot check blood level dilinoleoylphosphatidylcholine ( DLPC , main phosphatidylcholine specie PPC ) validate compliance . Alcohol intake monitor 3 method : patient diary , collateral history monthly blood test marker alcohol consumption ( carbohydrate deficient transferrin ) ( CDT ) . Liver biopsy perform end 3 year specimens analyze two pathologist unaware patient ' identification treatment regimen . Fibrosis major criterion , assessment additional area , virologic response examine drinker non-drinkers . 1 . Fibrosis : The primary statistical analysis compare PPC placebo group regard change fibrosis score baseline value 36 month treatment . The primary fibrosis end point histological degree fibrosis grade liver biopsy accord Ishak et al ( 1995 ) . Furthermore , count number α-smooth muscle actin ( SMA ) express stellate cell ( Reeves et al , 1996 ) , principal collagen produce cell . Activation stellate cell transformation myofibroblast-like cell demonstrate experimental fibrosis ( Mak et al , 1984 , 1994 ) . Smooth muscle actin α actin isoform typical smooth muscle cell ( Skalli et al , 1986 ) , may localize stellate cell human liver . Its expression stellate cell consider indication phenotypic modulation stellate cell myofibroblasts . In human liver appearance smooth muscle actin α closely related process hepatic fibrosis ( Reeves et al , 1996 ) formation cirrhotic nodule ( Nouchi et al , 1991 ) . In addition , circulate break-down product collagen component extracellular matrix ( ECM ) use marker liver pathology . These include laminin , major noncollagenous glycoprotein basement membrane . Indeed , extracellular basement membrane undergo continuous turnover elevation laminin describe sera patient alcoholic liver disease ( Niemelä et al . 1988 ; Sato et al . 1986 ) . Tenascin , molecule express proliferate ECM , TIMP-1 inhibitor matrix degrade metalloproteinases ( MMPs ) , collagen IV , collagen VI , molecule form filament large collagen fibril , N-terminal propeptide procollagen type III ( PIIINP ) , consider marker fibrogenesis , hyaluronic acid ( HA ) , ubiquitous glycosaminoglycan high extraction liver sinusoidal endothelium , MMP-2 . All assess marker fibrosis , specifically patient chronic hepatitis C ( Kasahara et al , 1997 ; McHutchison et al , 2000 ; Kojima et la , 2001 ; Murawaki et al , 2001 ) subject also drinker . 2 . Sustained virologic response , define absence plasma HCV RNA minimum 24 week antiviral treatment complete .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Adult patient ( 67 year old ) eligible study positive HCV RNA test polymerase chain reaction ( quantitative test ) , qualitative test positive quantitative negative , undergone liver biopsy within one year entry , available analysis ( vide infra ) whose result consistent diagnosis chronic hepatitis least moderate inflammation , fibrosis score least 2/6 accord Ishak et al ( 1995 ) , exclude complete cirrhosis . In term drink , men comprise `` abstainer '' ( less 12 drink past year ) , drink lightly ( 113 drink per month ) moderately ( 414 drink per week ) ( Dufour , 1999 ) . For woman age 50 year , level reduce half . A drink define : 12 ounce regular beer , 5 ounce wine 1.5 ounce distil spirit ( 80 proof ) ( Nutrition Your Health , 1990 ) .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>67 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Chemical Compounds-drugs</keyword>
	<keyword>Human Subjects- adult</keyword>
	<keyword>Gastrointestinal System-liver</keyword>
	<keyword>Pathology</keyword>
</DOC>